1. Home
  2. ESEA vs AURA Comparison

ESEA vs AURA Comparison

Compare ESEA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

N/A

Current Price

$64.25

Market Cap

557.0M

ML Signal

N/A

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

N/A

Current Price

$6.58

Market Cap

631.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESEA
AURA
Founded
2005
2007
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.0M
631.6M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
ESEA
AURA
Price
$64.25
$6.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
★ $91.75
$16.60
AVG Volume (30 Days)
22.3K
★ 854.5K
Earning Date
11-17-2026
11-16-2026
Dividend Yield
★ 5.06%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.94
N/A
P/E Ratio
$3.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.00
$4.73
52 Week High
$79.67
$9.54

Technical Indicators

Market Signals
Indicator
ESEA
AURA
Relative Strength Index (RSI) 32.99 53.85
Support Level $59.55 $6.04
Resistance Level $73.19 $6.90
Average True Range (ATR) 2.24 0.32
MACD -0.17 0.04
Stochastic Oscillator 10.46 76.97

Price Performance

Historical Comparison
ESEA
AURA

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: